Allogene Therapeutics Inc (ALLO)
2.43
-0.09
(-3.57%)
USD |
NASDAQ |
May 28, 16:00
2.42
-0.01
(-0.41%)
After-Hours: 20:00
Allogene Therapeutics Revenue (TTM): 0.065M for March 31, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 0.065M |
December 31, 2023 | 0.073M |
September 30, 2023 | 0.077M |
June 30, 2023 | 0.083M |
March 31, 2023 | 0.125M |
Date | Value |
---|---|
December 31, 2022 | 0.156M |
September 30, 2022 | 75.85M |
June 30, 2022 | 75.85M |
March 31, 2022 | 75.80M |
December 31, 2021 | 114.09M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
0.065M
Minimum
Mar 2024
114.09M
Maximum
Dec 2021
34.22M
Average
0.1405M
Median
Revenue (TTM) Benchmarks
ANI Pharmaceuticals Inc | 517.46M |
Vaxart Inc | 10.61M |
Agenus Inc | 161.42M |
BioCryst Pharmaceuticals Inc | 355.40M |
Stereotaxis Inc | 27.10M |